Cabozantinib (Cabometyx®), in combination with nivolumab (Opdivo®), is indicated for the first-line treatment of advanced renal cell carcinoma in adults.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||28/03/2022|
|Rapid review completed||11/05/2022|
|Rapid Review outcome||A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of cabozantinib (Cabometyx®) in combination with nivolumab compared with the current standard of care, on the basis of the proposed price relative to currently available therapies.|